SEC Form 4 · accession 0001140361-17-005453
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel M Junius
Director
Period of report
Feb 8, 2017
Accepted (ET)
Feb 9, 2017 · 5:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 8, 2017 | M | 3,000 | $64.69 | A | 5,495 | D | |
| Common StockF1 | Feb 8, 2017 | S | 3,000 | $141.7545 | D | 2,495 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)F3,F2 | $64.69 | Feb 8, 2017 | M | 3,000 | D | — | May 6, 2024 | Common Stock | 3,000 | 2,964 | D |
Explanation of responses
- F1Represents the weighted average sales price of the shares sold ranging from a low of $141.7031 to a high of $141.7765 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F2Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 2,987 shares on May 7, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split").? The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F3Not applicable.